Cancer drugs: expediting the review process
Australia’s drug regulatory system has served us well in the past and as a result we have one the world’s best cancer survival rates.
The future challenge is ensuring timely access continues to be available for the best of the large and increasing number of new high cost targeted therapies that are showing efficacy across a range of cancers.
Other countries, including the United States, Canada, Japan, Europe and New Zealand, have accelerated access schemes for important new treatments. I advocate for a similar scheme in Australia.